Last reviewed · How we verify
rhuMAb 2C4 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
rhuMAb 2C4 (rhuMAb 2C4) — Genentech, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| rhuMAb 2C4 TARGET | rhuMAb 2C4 | Genentech, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- rhuMAb 2C4 CI watch — RSS
- rhuMAb 2C4 CI watch — Atom
- rhuMAb 2C4 CI watch — JSON
- rhuMAb 2C4 alone — RSS
Cite this brief
Drug Landscape (2026). rhuMAb 2C4 — Competitive Intelligence Brief. https://druglandscape.com/ci/rhumab-2c4. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab